Robert A Honkanen
Overview
Explore the profile of Robert A Honkanen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oganov A, Chou T, Hanson P, Abazari A, Kung P, Weissbart S, et al.
Clin Ophthalmol
. 2024 Aug;
18:2369-2380.
PMID: 39193320
Purpose: The aim of the research was to evaluate the use of teleophthalmology at a university practice during the COVID-19 pandemic, specifically examining precision, effectiveness, and patient satisfaction. Patients And...
2.
Jiang Z, Chernoff D, Galenchik-Chan A, Tomorri D, Honkanen R, Duong T, et al.
Front Ophthalmol (Lausanne)
. 2024 Jul;
4:1385495.
PMID: 38984144
Purpose: Blood flow (BF) of the retinal and choroidal vasculatures can be quantitatively imaged using MRI. This study sought to improve methods of data acquisition and analysis for MRI of...
3.
Huang W, Huang L, Wen Z, Honkanen R, Rigas B
J Ocul Pharmacol Ther
. 2023 May;
39(4):279-289.
PMID: 37172294
To evaluate the hypothesis that 3 novel compounds, OXT-328, Q-922, and CL-717 show efficacy in the treatment of oxygen-induced retinopathy (OIR) and whether or not their route of administration is...
4.
Huang W, Tourmouzis K, Perry H, Honkanen R, Rigas B
Exp Ther Med
. 2021 Oct;
22(6):1394.
PMID: 34650642
Dry eye disease (DED), which is a prevalent disease that still lacks successful treatment options, remains a major challenge in ophthalmology. Multiple animal models of DED have been used to...
5.
Huang W, Wen Z, Saglam M, Huang L, Honkanen R, Rigas B
J Ocul Pharmacol Ther
. 2021 Jun;
37(6):321-330.
PMID: 34152861
Inflammation of the ocular surface is central to dry eye disease (DED). The anti-inflammatory agent phospho-sulindac (PS) at a high dose was efficacious against DED in a rabbit model. We...
6.
Honkanen R, Huang L, Rigas B
J Vis Exp
. 2020 Feb;
(155).
PMID: 32065120
Dry eye disease (DED), a multifactorial inflammatory disease of the ocular surface, affects 1 in 6 humans worldwide with staggering implications for quality of life and health care costs. The...
7.
Honkanen R, Huang L, Huang W, Rigas B
J Vis Exp
. 2020 Jan;
(155).
PMID: 31984964
Dry eye disease (DED) is a complex disease with multiple etiologies and variable symptoms, having ocular surface inflammation as its key pathophysiologic step. Despite advances in our understanding of DED,...
8.
Honkanen R, Huang L, Xie G, Rigas B
Transl Res
. 2018 Apr;
198:58-72.
PMID: 29702077
Dry eye disease (DED) currently has no satisfactory treatment partly because of the lack of informative animal models. We evaluated the anti-inflammatory phosphosulindac (PS) for the treatment of DED using...
9.
Hazlewood R, Roos B, Solivan-Timpe F, Honkanen R, Jampol L, Gieser S, et al.
Hum Mutat
. 2015 Jan;
36(3):369-78.
PMID: 25581579
Patients with a congenital optic nerve disease, cavitary optic disc anomaly (CODA), are born with profound excavation of the optic nerve resembling glaucoma. We previously mapped the gene that causes...
10.
Honkanen R, Baba F, Sibony P, Prabhu S
Retin Cases Brief Rep
. 2014 Nov;
5(1):73-5.
PMID: 25389687
Purpose: The purpose of this study was to report a case of ischemic central retinal vein occlusion (CRVO) caused by optic nerve head drusen. Methods: Case report and review of...